Dupixent® (dupilumab) approved as the first-ever biologic medicine in japan for patients with chronic obstructive pulmonary disease (copd)

Following recent approvals in the eu, china and the u.s., this approval was based on pivotal phase 3 results in adults with elevated eosinophils

REGN Ratings Summary

REGN Quant Ranking